Item 6. EXHIBITS

The exhibits listed below are filed or furnished as part of this Quarterly Report on Form 10-Q.

EXHIBIT INDEX


Exhibit Number						Description of Exhibit
4.1						Amended and Restated Certificate of Incorporation, as amended. Incorporated by reference to Exhibit 3.1 to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2012.

4.2						Certificate of Amendment to the Certificate of Incorporation. Incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on March 27, 2015.

4.3						Certificate of Amendment of Biogen Inc.’s Amended and Restated Certificate of Incorporation, as amended. Incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on June 8, 2021.

4.4						Certificate of Amendment of Biogen Inc.’s Amended and Restated Certificate of Incorporation, as amended. Incorporated by reference to Exhibit 4.4 to the Registrant’s Registration Statement on Form S-8 filed on June 20, 2024.

4.5						Fifth Amended and Restated Bylaws. Incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on December 12, 2023.

10.1*						Biogen Inc. 2024 Omnibus Equity Plan. Filed as Appendix C to Biogen’s Definitive Proxy Statement on Schedule 14A filed on April 26, 2024.

10.2*						Biogen Inc. 2024 Employee Stock Purchase Plan. Filed as Appendix D to Biogen’s Definitive Proxy Statement on Schedule 14A filed on April 26, 2024.

10.3+*						Form of performance share award agreement under the Biogen Inc. 2024 Omnibus Equity Plan.

10.4+*						Form of restricted stock unit award agreement under the Biogen Inc. 2024 Omnibus Equity Plan.

10.5+*						Form of restricted stock unit award agreement for non-employee Director's under the Biogen Inc. 2024 Omnibus Equity Plan.

31.1+						Certification of the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2+						Certification of the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1++						Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101++						The following materials from Biogen Inc.’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, formatted in iXBRL (Inline Extensible Business Reporting Language): (i) the Condensed Consolidated Statements of Income, (ii) the Condensed Consolidated Statements of Comprehensive Income, (iii) the Condensed Consolidated Balance Sheets, (iv) the Condensed Consolidated Statements of Cash Flow, (v) the Condensed Consolidated Statements of Equity and (vi) Notes to Condensed Consolidated Financial Statements.

104++						The cover page from this Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, formatted in Inline XBRL.

+ Filed herewith

++ Furnished herewith

Management contract or compensatory plan or arrangement

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.



BIOGEN INC.

/s/ Michael R. McDonnell
Michael R. McDonnell

Chief Financial Officer
(principal financial officer)

August 1, 2024

Previous: Item 5. OTHER INFORMATION